Inhaled Vaporized Cannabis Yields No Analgesic Benefit in Patients With SCD
Inhalation of vaporized cannabis did not significantly reduce self-reported pain levels or disease-related symptoms in adults with sickle cell disease (SCD) compared with placebo,...
Evaluating Selinexor in Patients With Relapsed/Refractory DLBCL
Oral selinexor demonstrated durable activity and a 28% response rate in patients with previously treated relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according...
Cutaneous Toxicities Are Underestimated in Patients With MPNs Receiving Hydroxyurea
A prospective study from Germany has found that, in patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs), treatment with hydroxyurea (hydroxycarbamide) is associated with a substantially...
Combination of Tafasitamab and Lenalidomide Leads to Durable Responses in Relapsed/Refractory DLBCL
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic cell transplantation, treatment with a combination of the...
Givosiran Reduces Porphyria Attacks Among Patients With Acute Intermittent Porphyria
Compared with placebo, treatment with the RNA interference therapy givosiran lowered the rate of porphyria attacks in patients with acute intermittent porphyria, the most...
Higher Hydroxyurea Dose Does NOHARM in Sub-Saharan African Children With Sickle Cell Disease
According to results from the NOHARM (Novel use Of Hydroxyurea in an African Region with Malaria) maximum tolerated dose (MTD) trial, dose-escalated hydroxyurea controlled...
Can Risk-Adapted EPOCH-R Replace Intensive Therapy for Burkitt Lymphoma?
Adults with Burkitt lymphoma are typically treated with dose-intensive combination chemotherapy derived from pediatric leukemia regimens, which the study investigators noted is “acutely toxic...
Study Supports Use of AHCT Over VMP as Intensification in Newly Diagnosed Myeloma
In patients with newly diagnosed myeloma, following induction chemotherapy, early autologous hematopoietic cell transplantation (AHCT) as intensification therapy prolonged progression-free survival (PFS), compared with...
Pomalidomide-Based Regimen Associated With Durable Response in Lenalidomide-Refractory Myeloma
Treatment with a regimen consisting of pomalidomide, low-dose dexamethasone, and daratumumab as either second- or third-line therapy induced durable responses in a high proportion...
Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE
In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.